Roche Drops Phase III Plans for Emugrobart in Two Muscle Wasting Diseases

Roche drops Phase III plans for emugrobart in two muscle wasting diseases

Roche will no longer progress emugrobart to late-stage trials in FSHD and SMA, as the drug has failed to demonstrate muscle-building efficacyThe post Roche drops Phase III plans for emugrobart in two muscle wasting diseases appeared first on Clinical Trials Arena.

Genentech culls muscle-preserving drug in genetic diseases, raising questions about obesity trial

Roche's subsidiary Genentech has called off the late-stage development of a muscle-building drug in two rare genetic conditions, spinal muscular atrophy (SMA) and facioscapulohumeral muscular dystrophy (FSHD). The move raises questions about whether the drug ...